CA Patent

CA2195677C — Endothelin antagonists

Assigned to AbbVie Bahamas Ltd · Expires 2005-11-08 · 21y expired

What this patent protects

A compound of formula (I) or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.

USPTO Abstract

A compound of formula (I) or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.

Drugs covered by this patent

Patent Metadata

Patent number: CA2195677C
Jurisdiction: CA
Classification: —
Expires: 2005-11-08
Drug substance claim: No
Drug product claim: No
Assignee: AbbVie Bahamas Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.